166 related articles for article (PubMed ID: 28139373)
1. Development of Caco-2 cells co-expressing CYP3A4 and NADPH-cytochrome P450 reductase using a human artificial chromosome for the prediction of intestinal extraction ratio of CYP3A4 substrates.
Takenaka T; Kazuki K; Harada N; Kuze J; Chiba M; Iwao T; Matsunaga T; Abe S; Oshimura M; Kazuki Y
Drug Metab Pharmacokinet; 2017 Feb; 32(1):61-68. PubMed ID: 28139373
[TBL] [Abstract][Full Text] [Related]
2. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of electron transfer between NADPH-cytochrome P450 reductase and cytochrome P450 3A4.
Farooq Y; Roberts GC
Biochem J; 2010 Dec; 432(3):485-93. PubMed ID: 20879989
[TBL] [Abstract][Full Text] [Related]
4. Development of Caco-2 cells expressing four CYPs via a mammalian artificial chromosome.
Ohta Y; Kazuki K; Abe S; Oshimura M; Kobayashi K; Kazuki Y
BMC Biotechnol; 2020 Aug; 20(1):44. PubMed ID: 32819341
[TBL] [Abstract][Full Text] [Related]
5. Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions.
Mishin V; Heck DE; Laskin DL; Laskin JD
Toxicol Sci; 2014 Oct; 141(2):344-52. PubMed ID: 25061110
[TBL] [Abstract][Full Text] [Related]
6. Liver microsomal lipid enhances the activity and redox coupling of colocalized cytochrome P450 reductase-cytochrome P450 3A4 in nanodiscs.
Liu KC; Hughes JMX; Hay S; Scrutton NS
FEBS J; 2017 Jul; 284(14):2302-2319. PubMed ID: 28618157
[TBL] [Abstract][Full Text] [Related]
7. Stable expression of human cytochrome P450 3A4 in conjunction with human NADPH-cytochrome P450 oxidoreductase in V79 Chinese hamster cells.
Schneider A; Schmalix WA; Siruguri V; de Groene EM; Horbach GJ; Kleingeist B; Lang D; Böcker R; Belloc C; Beaune P; Greim H; Doehmer J
Arch Biochem Biophys; 1996 Aug; 332(2):295-304. PubMed ID: 8806738
[TBL] [Abstract][Full Text] [Related]
8. Establishment of ten strains of genetically engineered Salmonella typhimurium TA1538 each co-expressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase sensitive to various promutagens.
Yamazaki Y; Fujita K; Nakayama K; Suzuki A; Nakamura K; Yamazaki H; Kamataki T
Mutat Res; 2004 Aug; 562(1-2):151-62. PubMed ID: 15279838
[TBL] [Abstract][Full Text] [Related]
9. Structural Dynamics of Cytochrome P450 3A4 in the Presence of Substrates and Cytochrome P450 Reductase.
Ducharme J; Sevrioukova IF; Thibodeaux CJ; Auclair K
Biochemistry; 2021 Jul; 60(28):2259-2271. PubMed ID: 34196520
[TBL] [Abstract][Full Text] [Related]
10. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase.
Hu M; Li Y; Davitt CM; Huang SM; Thummel K; Penman BW; Crespi CL
Pharm Res; 1999 Sep; 16(9):1352-9. PubMed ID: 10496649
[TBL] [Abstract][Full Text] [Related]
11. Reaction of human cytochrome P450 3A4 with peroxynitrite: nitrotyrosine formation on the proximal side impairs its interaction with NADPH-cytochrome P450 reductase.
Lin HL; Kenaan C; Zhang H; Hollenberg PF
Chem Res Toxicol; 2012 Dec; 25(12):2642-53. PubMed ID: 23016756
[TBL] [Abstract][Full Text] [Related]
12. Topological changes in the CYP3A4 active site probed with phenyldiazene: effect of interaction with NADPH-cytochrome P450 reductase and cytochrome b5 and of site-directed mutagenesis.
Yamaguchi Y; Khan KK; He YA; He YQ; Halpert JR
Drug Metab Dispos; 2004 Jan; 32(1):155-61. PubMed ID: 14709633
[TBL] [Abstract][Full Text] [Related]
13. Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.
Shaw PM; Hosea NA; Thompson DV; Lenius JM; Guengerich FP
Arch Biochem Biophys; 1997 Dec; 348(1):107-15. PubMed ID: 9390180
[TBL] [Abstract][Full Text] [Related]
14. Immobilized Cytochrome P450 for Monitoring of P450-P450 Interactions and Metabolism.
Bostick CD; Hickey KM; Wollenberg LA; Flora DR; Tracy TS; Gannett PM
Drug Metab Dispos; 2016 May; 44(5):741-9. PubMed ID: 26961240
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human cytochrome P450 3A4 activity by zinc(II) ion.
Kim JS; Yun CH
Toxicol Lett; 2005 Apr; 156(3):341-50. PubMed ID: 15763633
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a yeast system that stably expresses human cytochrome P450 reductase: application for the study of drug metabolism of cytochrome P450s in vitro.
Cheng J; Wan DF; Gu JR; Gong Y; Yang SL; Hao DC; Yang L
Protein Expr Purif; 2006 Jun; 47(2):467-76. PubMed ID: 16434211
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activities.
Lee SJ; Goldstein JA
Drug Metab Pharmacokinet; 2012; 27(6):663-7. PubMed ID: 22785258
[TBL] [Abstract][Full Text] [Related]
18. Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes.
Gan L; von Moltke LL; Trepanier LA; Harmatz JS; Greenblatt DJ; Court MH
Drug Metab Dispos; 2009 Jan; 37(1):90-6. PubMed ID: 18838505
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
20. Functional reconstitution of monomeric CYP3A4 with multiple cytochrome P450 reductase molecules in Nanodiscs.
Grinkova YV; Denisov IG; Sligar SG
Biochem Biophys Res Commun; 2010 Jul; 398(2):194-8. PubMed ID: 20599740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
